 Home > Active Ingredient News > Drugs Articles > China Pharmaceutical BD Trading Inventory October 2022

China Pharmaceutical BD Trading Inventory October 2022

 Last Update: 2022-11-15
 Source: Internet
 Author: User

Tags

commercial flooring systems

4 bases rna

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to the statistics of Meibai Capital, there were 8 BD transactions in China in October, including 1 cross-border asset purchase, 2 cross-border asset sales, and 5 domestic transactions
.

Cross-border asset buying

1.
JW Therapeutics and 2Seventy Bio announced a strategic cooperation to accelerate the development of T cell immunotherapy

On October 27, JW Therapeutics and 2seventy BIO announces a strategic partnership
.
The two parties will establish a platform for cell therapy translation and clinical development to accelerate the development of
T-cell immunotherapy products in Chinese mainland, Hong Kong and Macau.

Under the terms of the agreement, 2seventy will license JW Therapeutics to conduct MAGE-A4 cell therapy programs in Chinese mainland, Hong Kong and Macau, JW Therapeutics will be responsible for its development, manufacturing and commercialization in China, and 2seventy will be entitled to milestone payments and royalties
based on product revenue.
In addition, 2seventy can use early clinical data based on the collaborative project to develop the product
in other regions.
The completion of the transaction is subject to the approval of JW Therapeutics shareholders and other customary closing conditions
.

Cross-border asset selling

1.
$162 million! Reindeer Bio and Cabaletta Bio enter into a global licensing agreement

October 11, reindeer creatures with Cabaletta Bio jointly announces that Reindeer Bio has granted Cabaletta exclusive global rights to develop, manufacture and commercialize its clinically validated fully human CD19 sequence for Cabaletta in its products to modify T cells in the field of autoimmune diseases
.
Reindeer Bio will be eligible for up to two products, with a cumulative down payment of approximately $162 million plus potential development and commercialization milestone payments and sales shares
.
Reindeer Biotech has priority to use the licensed sequence to
develop and commercialize Cabaletta products in Greater China.

2.
Biosetu's wholly-owned subsidiary, Yuhe Pharmaceutical, reached a global licensing agreement with Syncromune of the United States on OX40 monoclonal antibody (YH002) to jointly develop intratumoral immunotherapy

On October 18, Biosetu (Beijing) Pharmaceutical Technology (Beijing) Co.
, Ltd.
, a wholly-owned subsidiary of Biosetu (Beijing) Pharmaceutical Technology Co.
, Ltd.
, announced an agreement with Syncromune, a clinical-stage US biopharmaceutical company, to jointly develop and commercialize intratumoral immunotherapy
based on Syncrovax™ technology.

Under the agreement, Syncromune will receive exclusive global development and commercialization rights
to intratumoral immunotherapies consisting of YH002 and other active ingredients for Syncrovax™ therapies.
YH002 and other active ingredients retain all worldwide rights and interests
in YH002 and other active ingredients except Syncrovax™.
Yuhe Pharma is expected to receive hundreds of millions of dollars in payments, including cash down payments assessed based on the clinical value of antibody molecules, key development and regulatory milestone payments, sales shares, and other commercial uses
based on Syncrovax™ combination therapies.
Yuhe Pharma will be responsible for drug manufacturing and supply, and Syncromune will be responsible for the clinical development and commercialization
of the product.

Transactions in China

1.
CSPC Group obtained an exclusive license!

On October 10, CSPC announced that CSPC Enbip Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the Group, has entered into an exclusive licensing agreement with Harbour Pharmaceuticals (Shanghai) Co.
, Ltd.
, pursuant to which Empip Pharmaceuticals has obtained an exclusive license from Shanghai Harbour Pharmaceuticals to develop, manufacture and commercialize bartolimab (HBM9161)
in Greater China, including Chinese mainland, Hong Kong, Macau and Taiwan.

In consideration of obtaining an exclusive license for the product in the region, Embip agreed to pay an initial payment of RMB150 million, up to RMB50 million for potential technology milestones, up to RMB400 million for potential development and regulatory milestones, and up to US$57.
5 million (approximately RMB411 million) for potential sales
milestones.
Enbip Pharmaceuticals also agreed to pay a tiered sales royalty
to Shanghai Harbour Pharmaceuticals based on the annual net sales of the product in the region.

2.
Dashi Pharmaceutical and ADC drug research and development new cutting-edge Yingen Biologics reached a project authorization agreement!

On October 11, Dashi Pharmaceutical officially signed an agreement
with Yingen Biologics, the world's leading ADC drug research and development.
The two parties reached an agreement on
the global rights and interests of Yingen Biologics to develop a new antibody conjugate drug (ADC) independently developed by Dashi Pharmaceutical, a bispecific antibody molecule DS005 with global first-in-class potential.
Dashi will receive an upfront payment and milestone payment, as well as a share of
commercial sales.

3.
Guangshengtang obtained 13.
5 million yuan from Ruitai ursodeoxycholic acid capsule preparation technology transfer

On October 11, Fujian Guangshengtang Pharmaceutical Co.
, Ltd.
announced that it intends to sign a "technology transfer contract" with Fujian Ruitai Pharmaceutical Technology Co.
, Ltd.
, in which Ruitai will transfer all the technology and corresponding information and all rights and interests and corresponding technical data of the ursodeoxycholic acid capsule preparation (specification: 250mg) owned by Ruitai to Guangshengtang for a transaction amount of RMB 13.
5 million
.

4.
Jimin Credible acquired Liaoyuan Pharmaceutical for 513 million

On October 14, Minova Pharmaceutical announced that it had signed a share transfer agreement
with Jimin Credible on Liaoyuan Pharmaceutical.
Minova Pharmaceutical intends to transfer its entire equity interest in Liaoyuan Pharmaceutical, namely 23,771,218 shares (approximately 84.
5661% of the total shares of Liaoyuan Pharmaceutical), to Jimin Credible for a transaction consideration of RMB512,581,515 (approximately RMB513 million).

Based on the valuation results of the Asset Appraisal Report and after friendly negotiation between the two parties to the transaction, it was agreed to determine the transaction consideration based on the valuation of 100% shares of Liaoyuan Pharmaceutical Co.
, Ltd.
of
606,131,197.
96 yuan (approximately 606 million).

5.
Salubris has entered the era of RNA drugs!

On October 25, Salubris announced that it had signed a cooperation and development agreement with Beijing Anlong Biopharmaceutical Co.
, Ltd.
, and the two parties will carry out in-depth cooperation
on the research and development of oligonucleotide drugs in the field of hypertension.

According to the agreement, Anlong Biologics will be responsible for the early development
of the project using the ANGO oligonucleotide drug technology platform with independent intellectual property rights.
Salubris is responsible for the late-stage development, clinical trials and marketing of
the product.
Salubris will acquire exclusive R&D and commercialization rights to the oligonucleotide drug worldwide, and the two parties will share future market and commercial benefits
.

Four summaries

brief summary

In recent years, cooperative technological innovation has become an important trend
in international pharmaceutical technology innovation.
A large number of domestic pharmaceutical enterprises seize the important opportunity of the international division of labor in new drug research and development, integrate into global technology integration, promote their own drug innovation and development, and look forward to the further development
of China's innovative drugs.
For more information on cross-border cooperation, please contact Metro Capital
.

For more information on cross-border cooperation, please contact Metro Capital
.

Meibai Capital is an asset trading and investment bank focusing on the healthcare sector in China, and is an important part of
Meibai Health's business.
Core Focus:

1.
BD Asset Transaction Advisory (Licensing Transactions, Commercial Partnerships, Joint Developments)

2.
FA equity transaction consulting (investment and financing, joint venture company formation, mergers and acquisitions)

3.
Buyer CDD Consulting (Consulting Consulting, Deal Sourcing Global Project Matchmaking, Deal Making Transaction Facilitation)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.